← Leaderboards
Periasamy Selvaraj
Emory University
$6,170,340
Attributed
$8,462,186
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $742.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,462,186 · 6
By mechanism
R01$7,636,575 · 4
R21$825,611 · 2
Top collaborators
- Christopher D Pack9 shared
- Dong Moon Shin4 shared
Most similar at Emory University
Same institution · by research overlap
- Christopher D Pack$4,540,154
- Frank E McDonald$2,161,216
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneCellsBaseImmune ResponseApplications GrantsProteinsMembranePreventCancer VaccinesAdjuvantTumor TissueImmunityVesicleTumorNeoplasm MetastasisVaccinationAntigensAutologousMalignant NeoplasmsMouse ModelTumor AntigensDesignVaccinesImmunotherapy
Grant awards (28)
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck$629,482
R01 · FY2025 · CA
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck$639,614
R01 · FY2024 · CA
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck$48,916
R01 · FY2024 · CA
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck$625,507
R01 · FY2023 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$480,895
R01 · FY2020 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$54,324
R01 · FY2020 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$468,979
R01 · FY2019 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$54,778
R01 · FY2019 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$483,484
R01 · FY2018 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$56,472
R01 · FY2018 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$482,114
R01 · FY2017 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$56,472
R01 · FY2017 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$502,655
R01 · FY2016 · CA · contact PI
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants$293,258
R01 · FY2013 · CA · contact PI
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants$311,976
R01 · FY2012 · CA · contact PI
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants$311,976
R01 · FY2011 · CA · contact PI
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants$321,625
R01 · FY2010 · CA · contact PI
Recombinant Fc receptor therapeutics for systemic lupus erythematosus$172,631
R21 · FY2010 · AR · contact PI
Glycolipid-anchored cytokines as breast cancer membrane vaccine adjuvants$321,625
R01 · FY2009 · CA · contact PI
Recombinant Fc receptor therapeutics for systemic lupus erythematosus$209,250
R21 · FY2009 · AR · contact PI
Fc receptor targeted therapy for immune hemolytic anemia$193,750
R21 · FY2009 · HL · contact PI
Fc receptor targeted therapy for immune hemolytic anemia$17,980
R21 · FY2009 · HL · contact PI
Fc receptor targeted therapy for immune hemolytic anemia$232,000
R21 · FY2008 · HL · contact PI
Regulation of CD32A in neutrophils$288,247
R01 · FY2007 · AI · contact PI
Regulation of CD32A in neutrophils$296,856
R01 · FY2006 · AI · contact PI
Regulation of CD32A in neutrophils$304,000
R01 · FY2005 · AI
Regulation of CD32A in neutrophils$304,000
R01 · FY2004 · AI
Regulation of CD32A in neutrophils$299,320
R01 · FY2003 · AI